CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.
Also called NCT06283888
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,200 participants
- Sponsor
- Registry
-
NCT06283888
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06283888. Randomized; no masking; primary purpose treatment. Start 2024-04-01 (anticipated); primary completion 2028-04-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
- Condition
- ACS - Acute Coronary Syndrome
- Condition
- CYP2C19 Polymorphism
- Intervention (Drug)
- CYP2C19 Genotype Guided DAPT
- Intervention (Drug)
- Conventional DAPT
- Lead sponsor
- Zunyi Medical College
Record details
- Record id
cardio:ct-nct06283888- Content hash
60d5404c0de1439dc6ec47f31aa9e35ffd7ebcc14246ed63c70ea2643f9509b8